Trial
NCT00101075
Title XELOX FOR SALIVARY GLAND CANCERS
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
National Cancer Institute (NCI); Sanofi-Synthelabo
Condition
Head and Neck Cancer
Intervention
Capecitabine
Why stopped
Slow Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-02-27